Quest Diagnostics Incorporated (DGX) - Stock Analysis
Last updated: Apr 5, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Quest Diagnostics rallied ~28.5% over 21 days on a Q4/FY2025 beat, above-Street FY2026 guidance, a $1B buyback expansion and 7.5% dividend hike; strong FCF and advanced diagnostics launches (Haystack MRD, CoLab expansion) support near-term continuation from pullbacks toward the 190â205 support band.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong FCF ⢠High leverage ⢠Tight liquidity DGX generates strong free cash flow and aboveâaverage returns on invested capital but carries meaningful leverage, high intangibles, tight nearâterm liquidity, and valuation with little margin for error.
Price Behavior
Key Price Behavior Insights: ⢠At moving average ⢠Twice-held support ⢠Rolled down from highs Support Level: $194â195 Resistance Level: $203â212 DGX is trading essentially at its last-month simple moving average (~$198), signaling a neutral short-term trend with nearest support $194â195 and resistance $203â212 (a decisive close above ~$204â205 would be bullish; a break below ~$194 would be bearish).
Sentiment & News
Key News Insights: ⢠AI & clinical gains ⢠Mixed institutional flows ⢠Near-term earnings Quest Diagnostics shows operational momentum in AI and clinical channels, mixed institutional buying/selling, a board addition, and a looming Q1 print on April 21.
AI Summary
Quest Diagnostics is transitioning from a volume-driven lab business to a higher-margin, innovation-led diagnostics companyâmaking execution of Project Nova, commercialization/payer coverage of advanced MRD tests, and disciplined deleveraging the decisive drivers of upside. If Nova ramps cleanly and payers cover high-value tests, upside is meaningful; if PAMA-like reimbursement cuts, rising employee medical costs, or execution slippage occur, valuation and margins are at material riskâhence HOLD/watch for income-focused investors rather than growth seekers.
Description
Quest Diagnostics is a provider of diagnostic testing and related information services in the U.S. and internationally, offering a spectrum of laboratory testing from routine to advanced clinical and anatomic pathology under multiple brands. Its customers include patients, clinicians, hospitals, health plans, employers and life insurers, and it delivers services through laboratories, patient service centers, physician-office phlebotomists, mobile clinicians and call centers. The company also supplies life-insurance risk assessment services and health care IT solutions and is headquartered in Secaucus, New Jersey, where it was founded in 1967.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 27 | Mar 6 | DGX | Quest Diagnostics Incorporated | Quest Diagnostics rallied ~28.5% over 21 days on a Q4/FY2025 beat, above-Street FY2026 guidance, a $1B buyback expansion and 7.5% dividend hike; strong FCF and advanced diagnostics launches (Haystack MRD, CoLab expansion) support near-term continuation from pullbacks toward the 190â205 support band. | Closed | -6.0% |